<SEC-DOCUMENT>0001654954-17-005826.txt : 20170623
<SEC-HEADER>0001654954-17-005826.hdr.sgml : 20170623
<ACCEPTANCE-DATETIME>20170623122942
ACCESSION NUMBER:		0001654954-17-005826
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170622
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170623
DATE AS OF CHANGE:		20170623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma, Inc
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52898
		FILM NUMBER:		17926975

	BUSINESS ADDRESS:	
		STREET 1:		469 JEAN-TALON WEST
		STREET 2:		3RD FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3N 1R4
		BUSINESS PHONE:		514-764-9698

	MAIL ADDRESS:	
		STREET 1:		469 JEAN-TALON WEST
		STREET 2:		3RD FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3N 1R4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sbfm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
U.S. SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
WASHINGTON, D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">
Form 8-K</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Current
Report Pursuant to Section 13 or 15(d) of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date of
Report (Date of earliest event reported):</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
June 22, 2017</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUNSHINE BIOPHARMA, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
name of small business issuer as specified in its
charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: Times New Roman; font-size: 13px; margin: 0px auto;">
<tr>
<td style="vertical-align: top; width: 33%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Colorado</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
000-0-52898</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
20-5566275</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(State
or other jurisdiction</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">of
incorporation)</font></div>
</td>
<td style="vertical-align: top; width: 34%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Commission
File Number)</font></div>
</td>
<td style="vertical-align: top; width: 34%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(IRS
Employer ID No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
469 Jean-Talon West</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
3rd&#xA0;Floor</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Montreal, Quebec, Canada H3N 1R4</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Address
of principal executive offices)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
(514) 764-9698</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Issuer&#x2019;s
Telephone Number)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;240.12b-2 of this chapter).&#xA0;</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;[X]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[&#xA0;&#xA0;]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[&#xA0;
] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[&#xA0;
] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[&#xA0;
] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[&#xA0;
] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 8.01 Other Events</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">We had
previously reported in our Form 10-K for our fiscal year ended
December 31, 2016 and Form 10-Q for the three months ended March
31, 2017, that pursuant to terms included in certain Subscription
Agreements with us, we had undertaken to obtain a valuation report
(the &#x201C;Report&#x201D;) on our issued and outstanding shares by
an independent valuation firm. To comply with this obligation, on
March 9, 2017, we engaged MNP LLP (&#x201C;MNP&#x201D;) to provide us
with such Report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On June
22, 2017, MNP issued its Report, which arrived at an estimated
<font style="font-style: italic">en bloc</font> Fair Market Value
at March 31, 2017 (the Valuation Date), of our issued and
outstanding shares, in the range of $977.0 million to $1,133.0
million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">MNP is
one of the largest public accountancy firms in Canada (www.mnp.ca).
The Montr&#xE9;al Valuation Practice (the &#x201C;Practice&#x201D;)
is engaged in the valuation of businesses, business ownership
interests, and securities and intangible assets in connection with
business combinations, distributions of listed and unlisted
securities, private placements, exchanges of shares, corporate and
financial reorganizations, going-private transactions, leveraged
buy-outs, fair value measurement of assets and liabilities for
purchase price allocation and annual impairment testing for
financial reporting pursuant to generally-accepted accounting
principles both in Canada and the United States. The Practice has
performed more than 3,000 valuations of public and private
companies throughout Canada and in the United States during the
past thirty years. Members of the Practice have also been playing
an active role in the Canadian and U.S. professional societies of
which they are accredited members, including serving on governing
boards and standards-promulgating committees.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">MNP is
not an insider, associate, or affiliate of our Company or any of
our affiliates, associates, or shareholders (collectively, the
&#x201C;Interested Parties&#x201D;). MNP does not own shares in the
Company, nor does it have any agreements, commitments, or
undertakings in respect of any future business involving any of the
Interested Parties. MNP&#x2019;s professional fees for services
rendered in preparing the Report were not contingent, in whole or
in part, on the conclusions reached therein and were based strictly
on the professional time expended on the engagement at their
standard hourly rates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">It is
not anticipated that the results of this valuation will have any
impact on our financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold">
Item 7.01 Regulation FD Disclosure</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px;">Our
Press Release relating to the Valuation described above is attached
as Exhibit 99.6 and is hereby incorporated.<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 9.01 Financial Statements and Exhibits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">(b)
Exhibits. The following exhibits are included in this
report:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 4%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="text-decoration: underline"><font style="font-family: Times New Roman; font-size: 13px">No.</font></font></font></div>
</td>
<td style="vertical-align: top; width: 96%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="text-decoration: underline"><font style="font-family: Times New Roman; font-size: 13px">Description</font></font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 4%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="sbfm_ex996.htm"><font style="font-family: Times New Roman; font-size: 13px">99.6</font></a></div>
</td>
<td style="vertical-align: top; width: 96%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Press
Release Announcing Valuation Report Release</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 4%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 96%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this amended report to be signed on its behalf by
the undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;margin-left:0px;">
<tr style="">
<td rowspan="1" style="width: 50%; vertical-align: top;">
<font style="font-family: Times New Roman; font-size: 13px">Dated:
June 22, 2017</font></td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SUNSHINE
BIOPHARMA, INC.</font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;"><font style="font-family: Times New Roman; font-size: 13px">(Registrant)</font></td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/</font>
<font style="font-family: Times New Roman; font-size: 13px">Dr.
Steve N. Slilaty</font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<font style="font-family: Times New Roman; font-size: 13px">Dr.
Steve N. Slilaty</font></td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;"><font style="font-family: Times New Roman; font-size: 13px">Chief Executive
Officer</font></td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;3</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line--><br></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>2
<FILENAME>sbfm_ex996.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold">&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Exhibit
99.6</font><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="logo.jpg" alt=""></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
For Immediate Release</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
June 26, 2017</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUNSHINE BIOPHARMA RELEASES RESULTS OF INDEPENDENT
VALUATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Montreal,
Quebec -- (ACCESSWIRE) -- Sunshine Biopharma Inc. (OTC Markets:
SBFM) is a pharmaceutical company focused on the research,
development and commercialization of drugs for the treatment of
various forms of cancer. The Company&#x2019;s lead anticancer
compound, Adva-27a, has proven effective at killing Multidrug
Resistant Cancer cells including Pancreatic Cancer cells,
Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine
Sarcoma cells (Results published in ANTICANCER RESEARCH, Volume 32,
Pages 4423-4432, October 2012).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company today received the results of an independent valuation it
had commissioned on its issued and outstanding shares. MNP LLP
(&#x201C;MNP&#x201D;) was retained to provide a Valuation Report (the
&#x201C;Report&#x201D;), on the estimated <font style="font-style: italic">en bloc</font> Fair Market Value at March 31,
2017 (the &#x201C;Valuation Date&#x201D;), of its issued and
outstanding shares. At the Valuation Date the value arrived at in
the Report was in the range of $977.0 million to $1,133.0 million.
The Company had commissioned the Report as part of an obligation it
had previously made to investors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">MNP is
one of the largest public accountancy firms in Canada (www.mnp.ca).
The Montr&#xE9;al Valuation Practice (the &#x201C;Practice&#x201D;)
is engaged in the valuation of businesses, business ownership
interests, and securities and intangible assets in connection with
business combinations, distributions of listed and unlisted
securities, private placements, exchanges of shares, corporate and
financial reorganizations, going-private transactions, leveraged
buy-outs, fair value measurement of assets and liabilities for
purchase price allocation and annual impairment testing for
financial reporting pursuant to generally-accepted accounting
principles both in Canada and the United States. The Practice has
performed more than 3,000 valuations of public and private
companies throughout Canada and in the United States during the
past thirty years. Members of the Practice have also been playing
an active role in the Canadian and U.S. professional societies of
which they are accredited members, including serving on governing
boards and standards-promulgating committees.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">MNP is
not an insider, associate, or affiliate of our Company or any of
our affiliates, associates, or shareholders (collectively, the
&#x201C;Interested Parties&#x201D;). MNP does not own shares in the
Company, nor does it have any agreements, commitments, or
undertakings in respect of any future business involving any of the
Interested Parties. MNP&#x2019;s professional fees for services
rendered in preparing the Report were not contingent, in whole or
in part, on the conclusions reached therein and were based strictly
on the professional time expended on the engagement at their
standard hourly rates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About Adva-27a</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small
molecule that has recently been shown to be effective at killing
Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer
cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published
in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).
Adva-27a is currently in the IND-Enabling stage of development. The
original U.S. patent covering Adva-27a was issued on August 7, 2012
under U.S. patent number 8,236,935. The Company is planning a Phase
I clinical trial of Adva-27a for Pancreatic Cancer in parallel to
the Phase I clinical trial of Adva-27a for multidrug resistant
Breast Cancer to be conducted at McGill University's Jewish General
Hospital in Montreal (Canada).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Safe Harbor Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
For Additional Information:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma Inc.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Camille
Sebaaly, CFO</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Tel.:
514-814-0464</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0563C1; font-family: Times New Roman; font-size: 13px">
camille.sebaaly@sunshinebiopharma.com</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !K /8# 2(  A$! Q$!_\0
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M^^C_ /%4?V]X7_Z!4W_?1_\ BJ/^$O\ Z"<B_P#!-?\ ^5A[_:K]Z_S/F?\
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M^"QGP<\0_L;65X-)M;E-8\7WNFVD\6BZ*4E&YE:0*!YD9<-&#C.W YQ79_\
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MOAI\>FZNPD4LE_;HL<V[T+$!_HXKWW_A*[W_ * E]_WTM?SR?\&[?_!3J/\
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M+VTU'3[R,2V]U:S+-#.AZ,CJ2K ^H-<5\:?V4OAG^T;I_P!E\>> O"?BV'G
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
